Literature DB >> 31969554

Development and Identification of a Nomogram Prognostic Model for Patients with Primary Clear Cell Carcinoma of the Liver.

Ziying Zhang1, Hui Xie2, Peng Chen3, Peiguo Cao1.   

Abstract

BACKGROUND Primary clear cell carcinoma of the liver (PCCCL) is an infrequent variant of primary hepatocellular carcinoma (HCC), we retrospectively performed a large population-based cohort study to elucidate the relationships between demographic, carcinoma- and therapy-specific variables and overall survival (OS). MATERIAL AND METHODS The Surveillance, Epidemiology and End Results (SEER) database was queried to extract data on 419 patients with pathologically confirmed PCCCL from 1988 to 2015. A nomogram with good accuracy was formulated to predict long-term survival of PCCCL patients. RESULTS The OS for PCCCL patients was 25.6 months (95% confidence interval [CI]: 22.2-29 months), the overall 1-year, 3-year, and 5-year survival rates were 59.5%, 39.3%, and 29.9%, respectively. Log-rank analysis revealed that there was no statistically significant discrepancy in clinical outcome between PCCCL and common-type HCC after propensity-matched analysis. Multivariate Cox analysis confirmed that larger lesions (>96 mm), distant metastases and elevated alpha-fetoprotein (AFP) levels were independent prognostic factors for undesirable outcome. Conversely, surgery was an independent protective factor (hazard ratio [HR]=0.23, 95% CI 0.17-0.31), which significantly boosted OS by virtually 35 months (47.3 months versus 12.7 months, P<0.001). Radiotherapy or chemotherapy was not associated with OS for PCCCL patients (both P>0.05). The nomogram incorporated 4 independent prognostic factors and its concordance index for predicting survival was 0.761. CONCLUSIONS The prognosis of PCCCL resembled that of common-type HCC. Larger lesions, distant metastases, and enhanced AFP levels were associated with unsatisfactory prognosis. Surgery fulfill favorable prognosis while radiotherapy or chemotherapy exerted no significant effects on survival.

Entities:  

Year:  2020        PMID: 31969554     DOI: 10.12659/MSM.919789

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  7 in total

1.  A web-based prognostic nomogram for the cancer specific survival of elderly patients with T1-T3N0M0 renal pelvic transitional cell carcinoma based on the surveillance, epidemiology, and end results database.

Authors:  Jinkui Wang; Jie Tang; Xiaozhu Liu; Dawei He
Journal:  BMC Urol       Date:  2022-05-24       Impact factor: 2.090

2.  Overexpression of GINS4 Is Associated With Tumor Progression and Poor Survival in Hepatocellular Carcinoma.

Authors:  Ziying Zhang; Peng Chen; Hui Xie; Peiguo Cao
Journal:  Front Oncol       Date:  2021-03-25       Impact factor: 6.244

3.  Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.

Authors:  Chengde Wu; Xiang Rao; Wei Lin
Journal:  Cancer Med       Date:  2020-12-12       Impact factor: 4.452

4.  A Web-Based Prediction Model for Overall Survival of Elderly Patients With Malignant Bone Tumors: A Population-Based Study.

Authors:  Jie Tang; JinKui Wang; Xiudan Pan
Journal:  Front Public Health       Date:  2022-01-11

5.  A web-based prediction model for overall survival of elderly patients with early renal cell carcinoma: a population-based study.

Authors:  Jinkui Wang; Jie Tang; Tiaoyao Chen; Song Yue; Wanting Fu; Zulong Xie; Xiaozhu Liu
Journal:  J Transl Med       Date:  2022-02-14       Impact factor: 5.531

6.  A Nomogram for Predicting Cancer-Specific Survival in Children With Wilms Tumor: A Study Based on SEER Database and External Validation in China.

Authors:  Xiaojun Tan; Jinkui Wang; Jie Tang; Xiaomao Tian; Liming Jin; Mujie Li; Zhaoxia Zhang; Dawei He
Journal:  Front Public Health       Date:  2022-04-07

7.  Overexpression of PKMYT1 Facilitates Tumor Development and Is Correlated with Poor Prognosis in Clear Cell Renal Cell Carcinoma.

Authors:  Peng Chen; Ziying Zhang; Xiang Chen
Journal:  Med Sci Monit       Date:  2020-10-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.